Compare BODI & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | QTTB |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 92.8M |
| IPO Year | N/A | 2018 |
| Metric | BODI | QTTB |
|---|---|---|
| Price | $10.45 | $5.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $13.00 |
| AVG Volume (30 Days) | 84.7K | ★ 238.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.38 | $1.40 |
| 52 Week High | $16.87 | $8.05 |
| Indicator | BODI | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 50.87 |
| Support Level | $9.55 | $5.51 |
| Resistance Level | $10.92 | $6.37 |
| Average True Range (ATR) | 1.48 | 0.52 |
| MACD | -0.56 | 0.06 |
| Stochastic Oscillator | 6.73 | 53.70 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).